Added to YB: 2025-09-12
Pitch date: 2025-09-10
TLX.AX [neutral]
Telix Pharmaceuticals Limited
-8.8%
current return
Author Info
No bio for this author
Company Info
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Market Cap
AUD 3.3B
Pitch Price
AUD 14.44
Price Target
N/A
Dividend
N/A
EV/EBITDA
87.60
P/E
228.98
EV/Sales
5.29
Sector
Biotechnology
Category
special_situation
Telix Pharmaceuticals (TLX-AU)
TLX.AX (quick overview): FDA rejected TLX250-CDx via CRL over manufacturing comparability issues at undisclosed related party Cyclotek (prior manufacturing fines, ex-CFO director, IPO shareholder). Second TLX250 rejection. Awaiting SEC subpoena on TLX591 disclosures. CEO Feb share sale looks prescient.
Read full article (1 min)